Zero Point Five Therapeutics develops targeted pharmacological treatments for soil-transmitted helminthiasis, a neglected tropical disease affecting millions globally. Their research focuses on creating safe and effective drug formulations to improve patient outcomes and reduce the burden of this parasitic infection.
Funding
$1.5M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Soil-transmitted helminthiasis, a neglected tropical disease, affects millions worldwide, causing significant health issues, especially in developing countries. Current treatments may have limitations in terms of safety, efficacy, or accessibility, leaving a gap in effective disease management.
Solution
Zero Point Five Therapeutics is developing targeted pharmacological treatments designed to combat soil-transmitted helminthiasis. Their approach focuses on creating drug formulations that are both safe and highly effective in treating this parasitic infection. By developing improved treatments, the company aims to enhance patient outcomes and reduce the overall burden of this widespread disease. The company's research is geared towards addressing the unmet needs in helminthiasis treatment, offering a potential solution to improve global health.
Target Audience
The primary beneficiaries are individuals in developing countries affected by soil-transmitted helminthiasis, as well as global health organizations and healthcare providers focused on neglected tropical diseases.
Features
Feature details are not available yet.